sameAs
Scale-up of HIV treatment through PEPFAR: a historic public health achievementHIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care?China's health assistance to Africa: opportunism or altruism?Mother and child both matter: reconceptualizing the prevention of mother-to-child transmission care continuumAssociation of adherence support and outreach services with total attrition, loss to follow-up, and death among ART patients in sub-Saharan AfricaGame changers: why did the scale-up of HIV treatment work despite weak health systems?Can the Success of HIV Scale-Up Advance the Global Chronic NCD Agenda?Transitioning to Country Ownership of HIV Programs in RwandaPredicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study.Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort studyHIV and people who use drugs in central Asia: confronting the perfect storm.Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.Nurse-led HIV services and quality of care at health facilities in Kenya, 2014-2016.HIV acquisition among women from selected areas of the United States: a cohort studyVenue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study.Addressing research priorities for prevention of HIV infection in the United StatesPreventing HIV infection in women.Characteristics and outcomes among older HIV-positive adults enrolled in HIV programs in four sub-Saharan African countries'Men usually say that HIV testing is for women': gender dynamics and perceptions of HIV testing in Lesotho.The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parametersRapid HIV self-testing: long in coming but opportunities beckon.A paradigm shift: focus on the HIV prevention continuum.Microfluidics-based diagnostics of infectious diseases in the developing world.Characteristics of multiple and concurrent partnerships among women at high risk for HIV infectionFactors associated with late antiretroviral therapy initiation among adults in MozambiqueHIV and H2O: tracing the connections between gender, water and HIV.Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D studyFamily matters: Co-enrollment of family members into care is associated with improved outcomes for HIV-infected women initiating antiretroviral therapy.Antiretroviral therapy: a promising HIV prevention strategy?Timing of initiation of antiretroviral drugs during tuberculosis therapy.Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis.Relationship of postprandial nonesterified fatty acids, adipokines, and insulin across gender in human immunodeficiency virus-positive patients undergoing highly active antiretroviral therapy.HIV treatment-as-prevention research: taking the right road at the crossroadsAdvanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011.Integration of antiretroviral therapy with tuberculosis treatment.
P50
Q26864517-5E178726-F6F3-4CAC-BF9D-5746F4E3AD40Q27010874-64CBD18B-9961-4A3C-8B03-E2FBBC245FE7Q28078571-5277BDA2-6158-49BE-BEC9-FA68ED9B6CFAQ28082436-19906EEB-212C-4850-AC00-6CBED6DF23BBQ28728715-5D1A47C5-E745-4B9B-B37E-A21ECCD5527DQ30062543-C4DBF5F5-535F-4CAC-ADC7-9FD5637100ECQ30240145-D573DC47-FFBD-4CF9-A70B-FA8C4F73B7B0Q30382104-9A1B180F-1FFA-474E-B29A-025877DDD443Q30573969-DE197F22-4F3E-428E-B7CD-223859E32E54Q31146395-B1875233-E7AE-496B-BBEF-CE8A358F2B14Q33294899-6B2789BB-A35E-4176-B652-658B92E73B97Q33389734-1423D6D0-3408-4611-97FF-A80ED107A992Q33404972-D54A384F-5EB7-4BEF-89F3-8644AACD225AQ33521080-48D716DC-8FE9-4CD8-8E3D-50DF63A5DC79Q33531746-753BDE9F-C2F1-4240-9DFC-5973C7A08063Q33552332-F9EBE721-FAB2-4A36-B888-011404C97609Q33602915-CD636DA0-6B0C-403E-9FBB-4A1D338AD186Q33640948-D4873BE6-3238-46B8-9CF3-6E8FC7E9191CQ33662739-4036609B-6B20-4477-8F68-3DF12A715400Q33714437-4A0CBBB3-0A25-4E66-95B7-0412EEB2A848Q33822456-63DBB6E9-095F-4878-A1FD-8D8AEF668DF2Q33855156-968C11B0-6004-4876-9592-9068261D5606Q33975574-577050E5-AB33-44D5-B8A9-DB53D73A8730Q33977549-E6396793-A065-4D85-B25D-08A728798BC0Q33985842-6337B940-D369-461F-9A9F-F45008CC90EEQ34037334-68CE9086-1F61-4B00-9CD6-272CEC844949Q34077706-2D9EFB63-65DF-4B7B-A473-3F6692EC4173Q34205112-D5BA8C38-69E5-4D84-ABA7-0170E1B2C028Q34231273-4C70081D-1DD0-419B-B27E-66936B21AE1AQ34277766-D7E62303-AB4C-4FB6-A90B-E11146CED836Q34278714-9296587D-FC9A-4DB5-B06D-C9DB60EAE1DCQ34474941-A1D5567D-D814-4414-985F-6AB560022096Q34612581-B97EB006-C429-42B2-8439-054F97972588Q34781053-2E5B9D2E-0B7A-4721-B507-E88B23D1895BQ34790184-A4B65DCB-45D9-4A8A-B492-F73D16FD9970Q35073163-AF0867EE-ECDC-4DF1-A6FE-0D4684C9D8E5Q35104013-077963F0-ABF8-44A5-8474-516A884E74DCQ35164755-164F12A5-8CD0-4D5A-BA77-54307C272DD6Q35180760-E12610FC-0A0B-4BF5-B320-E78A84D4ADAFQ35600960-66394613-380C-424B-A1E9-AF9F30BEA3D6
P50
description
Egiptuse arst
@et
Egyptian physician
@en
Egyptian physician
@en-ca
Egyptian physician
@en-gb
arts uit Egypte
@nl
dochtúir Éigipteach
@ga
doctoriță egipteană
@ro
dokter asal Mesir
@id
metgessa egípcia
@ca
mjeke egjiptiane
@sq
name
Wafaa El-Sadr
@ast
Wafaa El-Sadr
@de
Wafaa El-Sadr
@en
Wafaa El-Sadr
@es
Wafaa El-Sadr
@fr
Wafaa El-Sadr
@ga
Wafaa El-Sadr
@it
Wafaa El-Sadr
@nl
Wafaa El-Sadr
@oc
Wafaa El-Sadr
@pl
type
label
Wafaa El-Sadr
@ast
Wafaa El-Sadr
@de
Wafaa El-Sadr
@en
Wafaa El-Sadr
@es
Wafaa El-Sadr
@fr
Wafaa El-Sadr
@ga
Wafaa El-Sadr
@it
Wafaa El-Sadr
@nl
Wafaa El-Sadr
@oc
Wafaa El-Sadr
@pl
altLabel
Wafaa M El-Sadr
@en
وفاء الصدر
@en
prefLabel
Wafaa El-Sadr
@ast
Wafaa El-Sadr
@de
Wafaa El-Sadr
@en
Wafaa El-Sadr
@es
Wafaa El-Sadr
@fr
Wafaa El-Sadr
@ga
Wafaa El-Sadr
@it
Wafaa El-Sadr
@nl
Wafaa El-Sadr
@oc
Wafaa El-Sadr
@pl
P69
P214
P244
P101
P106
P19
P21
P213
0000 0000 3759 5889
P214
P244
n2003146958
P27
P31
P373
Wafaa El-Sadr
P496
0000-0003-3735-9781
P569
1950-01-01T00:00:00Z
P69
P735
P7859
lccn-n2003146958